Dietary Intervention on Atopy
NCT06547372
Allergic Diseases, Allergic Rhinitis
Singapore
View Trial DetailsNCT Number: NCT04798079
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions.
Primary Objectives:
* To study the role and interrelationships of established and novel clinical, environmental, biological, and genetic prenatal and early-life factors in the development and course of allergic diseases through age 3 years (or 6 years for those who choose to continue participation into SUNBEAM II), with an emphasis on atopic dermatitis and food allergy * To apply systems biology to identify mechanisms and biomarkers underlying the development of food allergy, atopic dermatitis, and their endotypes * To collect, process, and assay or store environmental and biological samples for current and future use in the study of allergic disease development
This study is active but is not currently recruiting participants.
0 year and older
All sexes
Observational
Arkansas Children's Hospital, Little Rock, Arkansas, United States
This is a prospective cohort study in which pregnant women (at any stage of pregnancy), the offspring's biologic father, and the offspring will be enrolled at study sites, and the offspring will be observed from birth to age 3 years. Enrollment of biological fathers will be attempted; however, enrollment of the mother or child is not dependent on enrollment of the biological father. The enrollment goal is at least 2500 mothers and their offspring having reached 12 months on study. Additionally, families will be offered the opportunity for the child participant to continue SUNBEAM through age 6 via the SUNBEAM II continuation protocol.
During the study, biological and environmental samples and questionnaire information will be collected from the parents and the children, and the children will be assessed for allergic diseases at clinic visits at ages 2, 5, 12, 24, and 36 months and for those who opt to continue participation, at 48, 60, and 72 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Pregnant Women-
Pregnant women who meet all of the following criteria are eligible for enrollment as study participants:
Biological Fathers-
Biological fathers who meet all of the following criteria are eligible for enrollment as study participants:
Exclusion criteria
Pregnant Women-
Pregnant women who meet any of these criteria are not eligible for enrollment:
Infants-
Infants who meet any of these criteria are not eligible for enrollment:
Biological Father-
----Note Regarding Legal Guardians who are not the Biological Parents:
Time frame: From 5 months to 72 months of age
To understand the early life origin and risk factors of child's IgE-mediated, immediate-type food allergy.
Based upon clinical assessments and diagnostic criteria for food allergy, in accordance with the Food Allergy Algorithm, per protocol.
Time frame: From 2 months to 72 months of age
To understand the early life origin and risk factors of child's atopic dermatitis (AD).
Atopic dermatitis is defined as the following since the last assessment (or since birth for the 2- and 5-month visits):
Any infant fulfilling these criteria but who, on examination by a suitably trained health professional, is deemed to have a different skin disease that explains the above findings will be classified as not having atopic dermatitis.
Time frame: From 5 months to 72 months of age
To understand the early life origin and risk factors of child's food allergy.
Sensitization to food allergens will be assessed using standard diagnostic methods: serum immunoglobulin E (IgE) testing and skin prick testing.
Time frame: From 12 months to 72 months of age
To understand the early life origin and risk factors of child's sensitization to aeroallergens, a risk factor for the development and severity of asthma.
Sensitization to aeroallergens will be assessed using standard diagnostic methods: serum immunoglobulin E (IgE) testing and skin prick testing.
Time frame: Up to 36 months of age
To understand the early life origin and risk factors of child's recurrent wheezing.
Recurrent wheeze, assessed at age 3 years, will be defined as at least two episodes of wheezing during the first three years of life, with at least one episode between the ages of 24 and 36 months
Time frame: From 24 to 72 months of age
To understand the early life origin and risk factors of child's seasonal allergic rhinitis, a seasonal allergic reaction to pollen.
Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.
Time frame: From 24 to 72 months of age
To understand the early life origin and risk factors of child's seasonal allergic conjunctivitis, a form of eye allergy.
Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.
Time frame: From 24 to 72 months of age
To understand the early life origin and risk factors of child's perennial allergic rhinitis, characterized by nasal symptoms such as sneezing and runny nose that are present year round.
Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.
Time frame: From 24 to 72 months of age
To understand the early life origin and risk factors of child's perennial allergic rhinitis, characterized by nasal symptoms such as sneezing and runny nose that are present year round.
Defined by diagnostic criteria established for the Inner-City Asthma Consortium, per protocol.
Time frame: 72 months of age
To understand the early life origin and risk factors of child's asthma, characterized by wheezing and other respiratory symptoms. The determination of asthma will follow criteria from the Urban Environment and Childhood Asthma (URECA) study.
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Acronym: SUNBEAM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06547372
Allergic Diseases, Allergic Rhinitis
Singapore
View Trial DetailsNCT07148557
Allergic Diseases
Hefei, China
View Trial DetailsNCT03567707
Allergic Diseases, Asthma
New York, United States
View Trial DetailsNCT07532421
Allergic Diseases, Antibiotic
Beijing, Beijing Municipality, China
View Trial Details